Showing 1 - 5 results of 5 for search 'Michael W Cho', query time: 0.03s Refine Results
  1. 1
    Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen

    Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen by Vikram Srivastava, Ling Niu, Kruttika S. Phadke, Kruttika S. Phadke, Bryan H. Bellaire, Bryan H. Bellaire, Michael W. Cho, Michael W. Cho, Michael W. Cho

    Published 2021-03-01
    Get full text
    Article
  2. 2
    Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.

    Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. by Yali Qin, Saikat Banerjee, Aditi Agrawal, Heliang Shi, Marisa Banasik, Feng Lin, Kari Rohl, Celia LaBranche, David C Montefiori, Michael W Cho

    Published 2015-01-01
    Get full text
    Article
  3. 3
    How can vaccines against influenza and other viral diseases be made more effective?

    How can vaccines against influenza and other viral diseases be made more effective? by Peter L Nara, Gregory J Tobin, A Ray Chaudhuri, Jessie D Trujillo, George Lin, Michael W Cho, Simon A Levin, Wilfred Ndifon, Ned S Wingreen

    Published 2010-12-01
    Get full text
    Article
  4. 4
    HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA).

    HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA). by Catarina E Hioe, Michael Tuen, Gaia Vasiliver-Shamis, Yelina Alvarez, Kathleen C Prins, Sagarika Banerjee, Arthur Nádas, Michael W Cho, Michael L Dustin, Scott C Kachlany

    Published 2011-01-01
    Get full text
    Article
  5. 5
    Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy.

    Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. by Rafiq Nabi, Zina Moldoveanu, Qing Wei, Elizabeth T Golub, Helen G Durkin, Ruth M Greenblatt, Betsy C Herold, Marek J Nowicki, Seble Kassaye, Michael W Cho, Abraham Pinter, Alan L Landay, Jiri Mestecky, Pamela A Kozlowski

    Published 2017-01-01
    Get full text
    Article

Search Tools: